The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

To clarify the safety and efficacy of using uniform-sized drug-loaded embolic microspheres (E-TACE) of different particle sizes for graded embolization during TACE combined with Donafenib in the treatment of unresectable primary liver cancer. To determine whether this therapy can prolong the ORR, DCR, PFS, OS and other indicators.

NCT Number	NCT07180459
Lead Sponsor	Xuhua Duan
Conditions	Carcinoma, Hepatocellular Carcinoma
Enrollment	118 participants
Start Date	2025-10-10
Primary Completion	2026-10-10 (estimated)
Study Completion	2027-10-10 (estimated)
Updated on ClinicalTrials.gov	2025-09-18